- Home
- BRT vs PRQR Comparison
BRT vs PRQR Comparison
Compare BRT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- PRQR
- Stock Information
- Founded
- BRT 1972
- PRQR 2012
- Country
- BRT United States
- PRQR Netherlands
- Employees
- BRT N/A
- PRQR N/A
- Industry
- BRT Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- PRQR Health Care
- Exchange
- BRT Nasdaq
- PRQR Nasdaq
- Market Cap
- BRT 331.7M
- PRQR 309.5M
- IPO Year
- BRT N/A
- PRQR 2014
- Fundamental
- Price
- BRT $17.57
- PRQR $1.69
- Analyst Decision
- BRT Strong Buy
- PRQR Strong Buy
- Analyst Count
- BRT 3
- PRQR 6
- Target Price
- BRT $22.17
- PRQR $8.50
- AVG Volume (30 Days)
- BRT 19.3K
- PRQR 383.7K
- Earning Date
- BRT 05-07-2025
- PRQR 03-13-2025
- Dividend Yield
- BRT 5.61%
- PRQR N/A
- EPS Growth
- BRT N/A
- PRQR N/A
- EPS
- BRT N/A
- PRQR N/A
- Revenue
- BRT $97,274,000.00
- PRQR $20,235,014.00
- Revenue This Year
- BRT N/A
- PRQR $39.44
- Revenue Next Year
- BRT $5.73
- PRQR N/A
- P/E Ratio
- BRT N/A
- PRQR N/A
- Revenue Growth
- BRT 1.95
- PRQR 105.20
- 52 Week Low
- BRT $15.61
- PRQR $1.61
- 52 Week High
- BRT $20.22
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- BRT 46.90
- PRQR 27.75
- Support Level
- BRT $17.36
- PRQR $1.78
- Resistance Level
- BRT $19.01
- PRQR $1.87
- Average True Range (ATR)
- BRT 0.56
- PRQR 0.15
- MACD
- BRT 0.00
- PRQR -0.05
- Stochastic Oscillator
- BRT 12.73
- PRQR 0.00
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.